

**PROMIUS PHARMA LLC PRESENTS CLINICAL DATA
FROM TWO PHASE III STUDIES OF DFD-01
FOR THE TREATMENT OF MODERATE PSORIASIS.**

Princeton, NJ – October 20, 2015 – Promius Pharma presented findings from two Phase III studies for its investigational psoriasis drug, DFD-01 at the 2015 Fall Clinical Dermatology Conference in Las Vegas, Nevada in early October 2015. DFD-01 is a novel formulation of betamethasone dipropionate, 0.05% available in an emollient spray. Both studies, enrolling over 500 patients, met their primary clinical endpoint for the treatment of moderate psoriasis after 2 weeks of treatment (day 15).

The primary endpoint was the proportion of patients achieving treatment success at day 15 for both studies. In addition, both studies met a secondary endpoint of treatment success at day 29. Treatment success was analyzed using Cochran–Mantel–Haenszel.

Adult patients with moderate psoriasis were enrolled in both studies and randomized to receive DFD-01, augmented betamethasone dipropionate lotion or vehicle. Mean BSA was between 13% and 14% for all groups and there were no notable differences between groups or studies.

DFD-01 improved signs of erythema, scaling and elevation in target lesions, with many located in difficult to treat areas. Both DFD-01 and its Vehicle were well tolerated. According to the investigators, the majority of adverse events (AEs) were mild to moderate with no notable increases in adverse events between 2 and 4 weeks of treatment.

According to Kent Allenby, Vice President of Clinical Development for Promius Pharma, “Based on the efficacy and consistent tolerability that DFD-01 has demonstrated in these phase III clinical studies of moderate plaque psoriasis, we look forward to continue working with the U.S. F.D.A. to gain approval for this important new therapy.”

Promius Pharma plans to submit additional detailed data from these pivotal phase III studies for presentation at scientific meetings and submit manuscripts for publication in peer reviewed journal in 2015 and 2016.

#

About Psoriasis

Psoriasis is a chronic, inflammatory skin disease for which there is no cure. In plaque psoriasis, the most common type, patches of skin called lesions become inflamed and are covered by silvery white scales.^① A non-contagious disorder, psoriasis can occur on any part of the body, and can significantly alter a sufferer’s life both physically and mentally, including the ability to work, play and interact with others. According to the National Psoriasis Foundation, up to 400,000 people are diagnosed with psoriasis each year.¹

About Promius Pharma LLC

Promius Pharma is a wholly owned, branded specialty company, of Dr. Reddy’s Laboratories, Inc. It is located in Princeton, NJ. Promius Pharma is a focused,

leading-edge company that develops and markets innovative solutions for challenging dermatological conditions with an eye to the future to redefine therapeutic options for physicians and patients.

¹*American Psoriasis Foundation.* <http://www.psoriasis.org>.

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues. The company assumes no obligation to update any information contained herein.

To receive additional information on the Company, please visit our website at www.promiuspharma.com, which does not form part of this press release.

Company Contact:

Suzanne Lane
The Lane Communications Group
212.757.6880
slane@thelcgroup.com